Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311
Debt
Debt-to-Equity Ratio0.16
Current Ratio7.72
Quick Ratio7.48
Price-To-Earnings
Trailing P/E Ratio-24.44
Forward P/E Ratio-33.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$63.92 million
Price / Sales8.17
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book18.80
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-17,280,000.00
Net Margins-23.35%
Return on Equity-37.86%
Return on Assets-21.19%
Miscellaneous
Employees205
Outstanding Shares42,730,000
Market Cap$604.58 million
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) issued its quarterly earnings results on Monday, August, 6th. The biotechnology company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The biotechnology company had revenue of $19.01 million for the quarter, compared to analysts' expectations of $18.51 million. Vericel had a negative net margin of 23.35% and a negative return on equity of 37.86%. View Vericel's Earnings History.
When is Vericel's next earnings date?
What price target have analysts set for VCEL?
5 brokers have issued 1 year price targets for Vericel's stock. Their forecasts range from $14.00 to $17.00. On average, they expect Vericel's share price to reach $15.00 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Vericel.
What is the consensus analysts' recommendation for Vericel?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Spark Therapeutics (ONCE), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Solid Biosciences (SLDB), Editas Medicine (EDIT), Audentes Therapeutics (BOLD), DBV TECHNOLOGIE/S (DBVT), Adaptimmune Therapeutics (ADAP), Avrobio (AVRO), Autolus Therapeutics (AUTL) and Cellectis (CLLS).
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo, CEO, Pres & Director (Age 54)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 55)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Who are Vericel's major shareholders?
Vericel's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.03%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.
Which major investors are selling Vericel stock?
VCEL stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $12.22.
How big of a company is Vericel?
Vericel has a market capitalization of $604.58 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.
What is Vericel's official website?
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (NASDAQ VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
